Potential drug-drug interactions in infant, child, and adolescent patients in Children's Hospitals

Pediatrics

Volumn 135, Issue 1, 2015, Pages e99-e108

  Feinstein, James ^a,b   Dai, Dingwei ^c   Zhong, Wenjun ^c   Freedman, Jason ^d   Feudtner, Chris ^c,d  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIINFECTIVE AGENT; BUPIVACAINE; CARDIOVASCULAR AGENT; CEFTRIAXONE; DEXAMETHASONE; FENTANYL; FLUCONAZOLE; FUROSEMIDE; GASTROINTESTINAL AGENT; GLUCONATE CALCIUM; GLYCOPYRRONIUM BROMIDE; HEPARIN; IBUPROFEN; KETOROLAC; LINEZOLID; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; NAPROXEN; NARCOTIC ANALGESIC AGENT; ONDANSETRON; POTASSIUM CHLORIDE; PROMETHAZINE; PROPOFOL; RETINOL; ROCURONIUM; SUXAMETHONIUM; UNINDEXED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILD; CHILD HOSPITALIZATION; CHRONIC DISEASE; COHORT ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIURESIS; DRUG ANTAGONISM; DRUG INTERACTION; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; INFANT; IRON ABSORPTION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYOPATHY; PEDIATRIC HOSPITAL; PEPTIC ULCER; PRESCHOOL CHILD; QT PROLONGATION; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HOSPITAL; HOSPITALIZATION; PREVALENCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALIZATION; HOSPITALS, PEDIATRIC; HUMANS; INFANT; MALE; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84920463274     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2015     Document Type: Article

References (32)

1. Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med. 2012;166(1):9-16
2. Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2012;68(5):801-810
3. Shah SS, Hall M, Goodman DM, et al. Offlabel drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161(3): 282-290
4. Walsh KE, Landrigan CP, Adams WG, et al. Effect of computer order entry on prevention of serious medication errors in hospitalized children. Pediatrics. 2008; 121(3). Available at: www.pediatrics.org/cgi/content/full/121/3/e427
5. Aspden P; Institute of Medicine. US Committee on Identifying and Preventing Medication Errors. Preventing Medication Errors. Washington, DC: National Academies Press; 2007
6. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111-128
7. Freedman MD. Drug interactions: classification and systematic approach. Am J Ther. 1995;2(6):433-443
8. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014; 23(5):489-497
9. Children's Hospital Association. PHIS+: augmenting the Pediatric Health Information System with clinical data. Available at: www.childrenshospitals.org/phisplus/index.html. Accessed September 9, 2014
10. Rizkalla NA, Feudtner C, Dai D, Zuppa AF. Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis. Pediatr Crit Care Med. 2013;14(9):e394-e403
11. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. Chichester, West Sussex, UK: Wiley- Blackwell; 2012
12. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199
13. US Food and Drug Administration. National Drug Code directory. Available at: www.fda.gov/drugs/informationondrugs/ucm142438.htm. Accessed September 9, 2014
14. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4): 380-385
15. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367-374
16. Kupferberg N, Jones Hartel L. Evaluation of five full-text drug databases by pharmacy students, faculty, and librarians: do the groups agree? J Med Libr Assoc. 2004;92(1):66-71
17. Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. JAMA. 2012;307(13):1433-1435
18. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901-910
19. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drugdrug interactions. Expert Opin Drug Saf. 2012;11(1):83-94
20. Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667-675
21. Du W, Tutag Lehr V, Caverly M, Kelm L, Reeves J, Lieh-Lai M. Incidence and costs of adverse drug reactions in a tertiary care pediatric intensive care unit. J Clin Pharmacol. 2013;53(5):567-573
22. Carrasco-Garrido P, de Andrés LA, Barrera VH, de Miguel GA, Jiménez- García R. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006). BMC Health Serv Res. 2010;10:287
23. Hu X, Sapo M, Nenov V, et al. Predictive combinations of monitor alarms preceding in-hospital code blue events. J Biomed Inform. 2012;45(5):913-921
24. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003). 2004;44(2):136-141
25. Chao SD, Maibach HI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol. 2005;6(2):105-111
26. Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ, The USPDURAP. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res. 2000;61(8):540-548
27. Wong CM, Ko Y, Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother. 2008;42(12):1737-1748
28. Slight SP, Seger DL, Nanji KC, et al. Are we heeding the warning signs? Examining providers' overrides of computerized drug-drug interaction alerts in primary care. PLoS One. 2013;8(12):e85071
29. Hincapie AL, Warholak TL, Hines LE, Taylor AM, Malone DC. Impact of a drug-drug interaction intervention on pharmacy and medical students' knowledge and attitudes: a 1-year follow-up. Res Social Adm Pharm. 2012;8(5): 472-477
30. Harrington AR, Warholak TL, Hines LE, Taylor AM, Sherrill D, Malone DC. Healthcare professional students' knowledge of drug-drug interactions. Am J Pharm Educ. 2011;75(10):199
31. Lopes P, Nunes T, Campos D, et al. Gathering and exploring scientific knowledge in pharmacovigilance. PLoS One. 2013;8(12):e83016
32. White JE. A two stage design for the study of the relationship between a rare exposure and a rare disease. Am J Epidemiol. 1982;115(1):119-128